Royalty Capital Stock from 2010 to 2025

RPRX Stock

USD 30.75 0.20 0.65%

Royalty Pharma Capital Stock yearly trend continues to be fairly stable with very little volatility. Capital Stock will likely drop to about 92.3 K in 2025. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals

Capital Stock

First Reported

2010-12-31

Previous Quarter

97.2 K

Current Value

92.3 K

Quarterly Volatility

1.6 B

Credit Downgrade

Yuan Drop

Covid

Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 226 M, Total Revenue of 2.8 B or Research Development of 57.5 M, as well as many indicators such as Price To Sales Ratio of 10.69, Dividend Yield of 0.0361 or PTB Ratio of 3.83. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.

Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Capital Stock Growth Pattern

Below is the plot of the Capital Stock of Royalty Pharma Plc over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. Royalty Pharma's Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.

Capital Stock

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Capital Stock

Timeline

Royalty Capital Stock Regression Statistics

	Arithmetic Mean	2,051,610,784
	Geometric Mean	66,948,352
	Coefficient Of Variation	80.00
	Mean Deviation	1,538,631,520
	Median	3,282,516,000
	Standard Deviation	1,641,206,955
	Sample Variance	2693560.3T
	Range	3.3B
	R-Value	(0.84)
	Mean Square Error	848809.5T
	R-Squared	0.71
	Significance	0.000046
	Slope	(289,624,865)
	Total Sum of Squares	40403404T

Royalty Capital Stock History

	2025	92.3 K
	2024	97.2 K
	2023	108 K
	2022	107 K
	2021	106 K
	2020	102 K

Other Fundumenentals of Royalty Pharma Plc

Issuance Of Capital Stock

Royalty Pharma Capital Stock component correlations

	Total Assets	Total Stockholder Equity	Accounts Payable	Short Term Investments	Total Liab	Treasury Stock	Common Stock	Property Plant Equipment	Intangible Assets	Net Tangible Assets	Retained Earnings	Total Current Assets	Net Debt	Long Term Debt	Net Receivables	Long Term Debt Total	Net Invested Capital	Long Term Investments	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Current Deferred Revenue	Capital Surpluse
Total Assets		0.98	0.82	0.15	0.95	-0.23	0.15	-0.37	-0.24	0.93	0.95	0.84	0.73	0.3	0.48	0.3	0.66	0.85	0.85	-0.85	-0.32	0.43	-0.44	0.68
Total Stockholder Equity	0.98		0.84	0.13	0.92	-0.24	0.19	-0.36	-0.2	0.9	0.94	0.79	0.7	0.19	0.42	0.19	0.59	0.81	0.8	-0.8	-0.36	0.32	-0.43	0.59
Accounts Payable	0.82	0.84		-0.34	0.74	-0.2	-0.02	-0.26	-0.38	0.73	0.89	0.41	0.87	0.34	0.73	0.33	0.79	0.86	0.81	-0.77	-0.66	0.18	-0.7	0.77
Short Term Investments	0.15	0.13	-0.34		0.13	0.32	0.04	-0.33	0.16	0.16	0.0	0.44	-0.2	-0.08	-0.59	-0.08	-0.23	-0.03	0.03	-0.12	0.56	0.49	0.47	-0.24
Total Liab	0.95	0.92	0.74	0.13		-0.33	0.39	-0.38	-0.1	0.96	0.93	0.88	0.69	0.3	0.43	0.3	0.64	0.74	0.71	-0.7	-0.37	0.41	-0.38	0.61
Treasury Stock	-0.23	-0.24	-0.2	0.32	-0.33		-0.42	-0.68	0.09	-0.31	-0.28	-0.26	-0.18	-0.04	-0.06	-0.04	-0.14	-0.08	-0.02	0.01	0.22	0.0	0.1	-0.07
Common Stock	0.15	0.19	-0.02	0.04	0.39	-0.42		-0.16	0.54	0.37	0.23	0.36	-0.02	-0.25	-0.29	-0.25	-0.13	-0.24	-0.37	0.37	-0.24	-0.2	0.17	-0.31
Property Plant Equipment	-0.37	-0.36	-0.26	-0.33	-0.38	-0.68	-0.16		-0.27	-0.37	-0.36	-0.34	-0.26	-0.08	-0.15	-0.08	-0.23	-0.28	-0.26	0.26	0.15	-0.14	0.12	-0.22
Intangible Assets	-0.24	-0.2	-0.38	0.16	-0.1	0.09	0.54	-0.27		-0.13	-0.25	0.01	-0.4	-0.34	-0.42	-0.34	-0.45	-0.49	-0.52	0.51	0.12	-0.32	0.31	-0.51
Net Tangible Assets	0.93	0.9	0.73	0.16	0.96	-0.31	0.37	-0.37	-0.13		0.94	0.82	0.76	0.24	0.38	0.23	0.68	0.79	0.68	-0.7	-0.45	0.39	-0.22	0.63
Retained Earnings	0.95	0.94	0.89	0.0	0.93	-0.28	0.23	-0.36	-0.25	0.94		0.69	0.87	0.34	0.53	0.34	0.79	0.86	0.79	-0.77	-0.56	0.41	-0.5	0.71
Total Current Assets	0.84	0.79	0.41	0.44	0.88	-0.26	0.36	-0.34	0.01	0.82	0.69		0.33	0.19	0.16	0.19	0.33	0.52	0.58	-0.61	0.07	0.45	-0.12	0.38
Net Debt	0.73	0.7	0.87	-0.2	0.69	-0.18	-0.02	-0.26	-0.4	0.76	0.87	0.33		0.53	0.65	0.52	0.95	0.89	0.74	-0.7	-0.71	0.4	-0.57	0.84
Long Term Debt	0.3	0.19	0.34	-0.08	0.3	-0.04	-0.25	-0.08	-0.34	0.24	0.34	0.19	0.53		0.43	1.0	0.69	0.49	0.49	-0.42	0.03	0.71	-0.61	0.67
Net Receivables	0.48	0.42	0.73	-0.59	0.43	-0.06	-0.29	-0.15	-0.42	0.38	0.53	0.16	0.65	0.43		0.43	0.76	0.68	0.69	-0.63	-0.57	0.05	-0.7	0.86
Long Term Debt Total	0.3	0.19	0.33	-0.08	0.3	-0.04	-0.25	-0.08	-0.34	0.23	0.34	0.19	0.52	1.0	0.43		0.68	0.48	0.48	-0.42	0.04	0.71	-0.62	0.66
Net Invested Capital	0.66	0.59	0.79	-0.23	0.64	-0.14	-0.13	-0.23	-0.45	0.68	0.79	0.33	0.95	0.69	0.76	0.68		0.89	0.76	-0.72	-0.6	0.48	-0.62	0.94
Long Term Investments	0.85	0.81	0.86	-0.03	0.74	-0.08	-0.24	-0.28	-0.49	0.79	0.86	0.52	0.89	0.49	0.68	0.48	0.89		0.94	-0.93	-0.45	0.49	-0.49	0.91
Short Long Term Debt	0.85	0.8	0.81	0.03	0.71	-0.02	-0.37	-0.26	-0.52	0.68	0.79	0.58	0.74	0.49	0.69	0.48	0.76	0.94		-0.99	-0.24	0.51	-0.58	0.86
Capital Stock	-0.85	-0.8	-0.77	-0.12	-0.7	0.01	0.37	0.26	0.51	-0.7	-0.77	-0.61	-0.7	-0.42	-0.63	-0.42	-0.72	-0.93	-0.99		0.19	-0.53	0.46	-0.83
Net Working Capital	-0.32	-0.36	-0.66	0.56	-0.37	0.22	-0.24	0.15	0.12	-0.45	-0.56	0.07	-0.71	0.03	-0.57	0.04	-0.6	-0.45	-0.24	0.19		0.27	0.36	-0.45
Short Term Debt	0.43	0.32	0.18	0.49	0.41	0.0	-0.2	-0.14	-0.32	0.39	0.41	0.45	0.4	0.71	0.05	0.71	0.48	0.49	0.51	-0.53	0.27		-0.16	0.45
Current Deferred Revenue	-0.44	-0.43	-0.7	0.47	-0.38	0.1	0.17	0.12	0.31	-0.22	-0.5	-0.12	-0.57	-0.61	-0.7	-0.62	-0.62	-0.49	-0.58	0.46	0.36	-0.16		-0.59
Capital Surpluse	0.68	0.59	0.77	-0.24	0.61	-0.07	-0.31	-0.22	-0.51	0.63	0.71	0.38	0.84	0.67	0.86	0.66	0.94	0.91	0.86	-0.83	-0.45	0.45	-0.59

Click cells to compare fundamentals

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Capital Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Capital Stock	97.2 K	92.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Royalty Capital Stock from 2010 to 2025

Latest Royalty Pharma's Capital Stock Growth Pattern

Royalty Capital Stock Regression Statistics

Royalty Capital Stock History

Other Fundumenentals of Royalty Pharma Plc

Royalty Pharma Capital Stock component correlations

About Royalty Pharma Financial Statements

Also Currently Popular

Additional Tools for Royalty Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY